A Phase 1 interventional study of LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) and LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) in Healthy, sponsored by LigaChem Biosciences, Inc.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-25.
Sponsored by LigaChem Biosciences, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this clinical trial is to evaluate bioequivalence of "LCB01-0371 (Batch# 1650006)" and "LCB01-0371(Batch#3183817R) in healthy adult subject
LigaChem Biosciences, Inc. is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006) Period 2: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
Drug: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) · Drug: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
Period 1: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) Period 2: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
Drug: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R) · Drug: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
Oral administration
Oral administration
Pharmacokinetic evaluation: The observed maximum concentration(Cmax)
Pharmacokinetic parameters will be assessed using non-compartmental method
Time frame: 0-12hours
Pharmacokinetic evaluation:Area under the blood concentration-time curve (AUClast)
Area under the plasma concentration curve from zero until the last measurable concentration
Time frame: 0-12hours
Pharmacokinetic evaluation: Time to reach Cmax(Tmax)
Pharmacokinetic parameters will be assessed using non-compartmental method
Time frame: 0-12hours
Pharmacokinetic evaluation: Elimination half-life(t1/2)
Pharmacokinetic parameters will be assessed using non-compartmental method
Time frame: 0-12hours
Pharmacokinetic evaluation: Apparent total body clearance after extravascular administration(CL/F)
Pharmacokinetic parameters will be assessed using non-compartmental method
Time frame: 0-12hours
Pharmacokinetic evaluation:Apparent volume of distribution after extravascular administration(Vd/F)
Pharmacokinetic parameters will be assessed using non-compartmental method
Time frame: 0-12hours
Pharmacokinetic evaluation:Area under the blood concentration-time curve (AUCinf)
Area under the curve from time 0 extrapolated to infinite time
Time frame: 0-12hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2021 to primary completion in Jan 2021, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delpazolid
LigaChem Biosciences, Inc.